Newsroom
Press Center
Oct 29, 2026
Corporate and finance
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
Oct 29, 2026
Corporate and finance
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
Aug 28, 2026
COVID-19,Corporate and finance
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
Perspectives & Insights
Explore our blog for valuable insights and inspiring stories from our team as we fulfill our vision to spark transformation in global health.
September 9, 2026
Corporate
Partnerships
Research & Development
Bob Walker, MD, Executive Vice President, Head of Research & Development
August 11, 2026
Corporate
Partnerships
Research & Development
Video featuring Bob Walker, MD, Executive Vice President, Head of Research & Development
In the News
See what others are saying about Novavax.
Fierce Biotech
Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
Washington Business Journal
Novavax’s stock soars on expected revenue jump from big pharma deals
Pharmaceutical Executive
Expanding the Vaccine Landscape with New Technologies: Q&A with Silvia Taylor
Note: This section features articles written by external media outlets and journalists.
About Novavax
We tackle some of the world's most significant health challenges by leveraging our scientific expertise in vaccines and cutting-edge technology platform, including protein-based nanoparticles and Matrix-M® adjuvant.
